SCHEMBL7311015

SCHEMBL7311015

O=C(O)C1CCCN(C(=O)CCc2ccccc2)C1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.72
HPGD P15428 1/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
POLB P06746 1/20 0.70
NPC1 O15118 2/20 0.66
TDP1 Q9NUW8 1/20 0.66
NAAA Q02083 1/20 0.56
CHRNB2 P17787 4/20 0.56
CHRNA4 P43681 4/20 0.56
CHRNB4 P30926 3/20 0.56
CHRNA3 P32297 3/20 0.56
KDM4E B2RXH2 2/20 0.54
KMT2A Q03164 1/20 0.54
FKBP1A P62942 1/20 0.54
RAB9A P51151 1/20 0.53
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17646360 1.00 ALDH1A1 (0.72) ALDH1A1HPGDSMN1; SMN2POLBNPC1
SCHEMBL3919245 0.86 RAB9A (0.67) ALDH1A1HPGDSMN1; SMN2POLBRAB9A
SCHEMBL22170868 0.86 ALDH1A1 (0.68) ALDH1A1HPGDSMN1; SMN2POLBNPC1
SCHEMBL12849241 0.83 HPGD (0.71) ALDH1A1HPGDSMN1; SMN2POLBNPC1
SCHEMBL27755645 0.83 ALDH1A1 (0.56) ALDH1A1HPGDSMN1; SMN2POLBNPC1
SCHEMBL1221986 0.82 POLB (1.00) HPGDSMN1; SMN2POLBNPC1TDP1
SCHEMBL8540196 0.82 SMN1; SMN2 (0.70) ALDH1A1HPGDSMN1; SMN2POLBNPC1
SCHEMBL17087869 0.82 NPC1 (0.96) HPGDSMN1; SMN2POLBNPC1TDP1
SCHEMBL6285963 0.82 NPC1 (0.96) HPGDSMN1; SMN2POLBNPC1TDP1
SCHEMBL8540522 0.81 HPGD (0.68) ALDH1A1HPGDSMN1; SMN2POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11332464-B2 Inhibitors of lysine gingipain Cortexyme, Inc. (US) 2022-05-17 US disclosed
EP-3512846-A1 KETONE INHIBITORS OF LYSINE GINGIPAIN Cortexyme, Inc. (US) 2019-07-24 EP disclosed
WO-2018053353-A1 KETONE INHIBITORS OF LYSINE GINGIPAIN Cortexyme, Inc. (US) 2018-03-22 WO disclosed
EP-0520336-A2 Aldehyde derivatives and their use as calpain inhibitors FUJIREBIO Inc. (JP) 1992-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332464-B2 Inhibitors of lysine gingipain ENPEP, PHYKPL, PREP ALDH1A1 2355/4885HPGD 663/4885SMN1; SMN2 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.